Celsion Stock Forecast, Price & News

Celsion (NASDAQ:CLSN) Frequently Asked Questions

Is Celsion a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Celsion in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Celsion stock.
View analyst ratings for Celsion or view top-rated stocks.

How has Celsion's stock been impacted by COVID-19 (Coronavirus)?

Celsion's stock was trading at $0.99 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CLSN stock has decreased by 30.3% and is now trading at $0.69.
View which stocks have been most impacted by COVID-19.

Are investors shorting Celsion?

Celsion saw a decrease in short interest in the month of November. As of November 15th, there was short interest totaling 1,720,000 shares, a decrease of 27.1% from the October 31st total of 2,360,000 shares. Based on an average daily trading volume, of 961,300 shares, the days-to-cover ratio is currently 1.8 days.
View Celsion's Short Interest.

When is Celsion's next earnings date?

Celsion is scheduled to release its next quarterly earnings announcement on Friday, March 18th 2022.
View our earnings forecast for Celsion.

How were Celsion's earnings last quarter?

Celsion Co. (NASDAQ:CLSN) issued its quarterly earnings data on Monday, November, 15th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.02. Celsion had a negative trailing twelve-month return on equity of 39.72% and a negative net margin of 3,912.20%. During the same quarter in the previous year, the business posted ($0.17) EPS.
View Celsion's earnings history.

When did Celsion's stock split? How did Celsion's stock split work?

Celsion shares reverse split on the morning of Tuesday, May 30th 2017. The 1-14 reverse split was announced on Friday, May 26th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, May 26th 2017. An investor that had 100 shares of Celsion stock prior to the reverse split would have 7 shares after the split.

Who are Celsion's key executives?

Celsion's management team includes the following people:

• Michael H. Tardugno, Chairman, President & Chief Executive Officer
• Jeffrey Wayne Church, CFO, Secretary & SVP-Investor Relations
• Nicholas Borys, Chief Medical Officer & Senior Vice President
• Khursheed Anwer, Chief Scientific Officer & Executive VP
• Jason G. Fewell, Vice President-Preclinical Research

Who are some of Celsion's key competitors?

Some companies that are related to Celsion include PDS Biotechnology (PDSB), 9 Meters Biopharma (NMTR), Spectrum Pharmaceuticals (SPPI), Molecular Templates (MTEM), XOMA (XOMA), PLx Pharma (PLXP), Checkpoint Therapeutics (CKPT), Pieris Pharmaceuticals (PIRS), GX Acquisition (GXGX), CymaBay Therapeutics (CBAY), Syros Pharmaceuticals (SYRS), Citius Pharmaceuticals (CTXR), Neoleukin Therapeutics (NLTX), Immunic (IMUX) and Ovid Therapeutics (OVID).
View all of CLSN's competitors.

What other stocks do shareholders of Celsion own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Celsion investors own include Zosano Pharma (ZSAN), Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), Novan (NOVN), Dynavax Technologies (DVAX), SCYNEXIS (SCYX), ADMA Biologics (ADMA), Aeterna Zentaris (AEZS), Agenus (AGEN) and CBL & Associates Properties (CBL).

What is Celsion's stock symbol?

Celsion trades on the NASDAQ under the ticker symbol "CLSN."

Who are Celsion's major shareholders?

Celsion's stock is owned by many different institutional and retail investors. Top institutional shareholders include Morgan Stanley (2.69%), BlackRock Inc. (1.27%), Geode Capital Management LLC (0.87%), Two Sigma Advisers LP (0.08%), Two Sigma Investments LP (0.06%) and Jane Street Group LLC (0.04%). Company insiders that own Celsion stock include Alberto R Martinez Jr, Donald P Braun, Donald P Braun and Frederick J Fritz.
View institutional ownership trends for Celsion.

Which major investors are selling Celsion stock?

CLSN stock was sold by a variety of institutional investors in the last quarter, including Two Sigma Investments LP, BlackRock Inc., and Citadel Advisors LLC.
View insider buying and selling activity for Celsion or view top insider-selling stocks.

Which major investors are buying Celsion stock?

CLSN stock was purchased by a variety of institutional investors in the last quarter, including Morgan Stanley, Two Sigma Advisers LP, Geode Capital Management LLC, and Jane Street Group LLC. Company insiders that have bought Celsion stock in the last two years include Alberto R Martinez Jr, Donald P Braun, and Frederick J Fritz.
View insider buying and selling activity for Celsion or or view top insider-buying stocks.

How do I buy shares of Celsion?

Shares of CLSN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Celsion's stock price today?

One share of CLSN stock can currently be purchased for approximately $0.69.

How much money does Celsion make?

Celsion has a market capitalization of $59.73 million and generates $500 thousand in revenue each year. The biotechnology company earns $-21.48 million in net income (profit) each year or ($0.26) on an earnings per share basis.

How many employees does Celsion have?

Celsion employs 27 workers across the globe.

When was Celsion founded?

Celsion was founded in 1982.

What is Celsion's official website?

The official website for Celsion is www.celsion.com.

Where are Celsion's headquarters?

Celsion is headquartered at 997 LENOX DRIVE SUITE 100, LAWRENCEVILLE NJ, 08648.

How can I contact Celsion?

Celsion's mailing address is 997 LENOX DRIVE SUITE 100, LAWRENCEVILLE NJ, 08648. The biotechnology company can be reached via phone at (609) 896-9100, via email at [email protected], or via fax at 609-896-2200.